Navigation Links
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Date:8/27/2008

- Patients in the VELCADE, melphalan and prednisone arm demonstrated a significant survival benefit as well as a 30 percent complete response -

CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week's edition of the New England Journal of Medicine. The results showed a significant survival benefit and a 30 percent complete remission (CR) rate with VELCADE, melphalan and prednisone (VcMP) compared to 4 percent for melaphalan and prednisone (MP) alone in previously untreated multiple myeloma patients. Multiple myeloma is the second most common blood cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

"These data demonstrate that treatment with VELCADE plus melphalan and prednisone leads to a survival benefit and a high complete remission in previously untreated patients with multiple myeloma," said Professor Jesus San Miguel, M.D., Ph.D., Hematology Department Head, University Hospital of Salamanca and Principal Investigator of the trial. "The combination of VELCADE plus melphalan and prednisone is an important new option for these patients."

These data originally were presented at the 2007 American Society of Hematology (ASH) Annual Meeting. Based on these positive trial results, the U.S. Food and Drug Administration approved VELCADE for patients with previously untreated multiple myeloma on June 20, 2008. The Phase III VISTA trial was conducted by Millennium and its co-development partner Johnson & Johnson Pharmaceutical Research & Development, L.L.C. in 151 centers worldwide.

"We are proud to have these data published in such a highly esteemed journal," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "We're delighted that previously untreated multiple myeloma patient
'/>"/>

SOURCE Millennium
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
3. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
6. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
7. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
8. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
9. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009).... 30 Cytokine PharmaSciences, Inc.... of CPSI-2364, its orally active, small-molecule i...pro-inflammatory cytokines. Results of the safety... volunteers confirm the safety of this compound in... subjects completed the study, including those rec...
(Date:11/30/2009)...PRNewswire/ -- The Simmons law firm,s Trent Miracl...ing thousands of women that were seriously injured...rol pill manufactured and marketed by Bayer Pharma...istrict Litigation has ordered that all federal Ya...idated and centralized for pretrial litigation in ...
(Date:11/30/2009)... 30 According to Millennium Resear...chnology market intelligence, the nearly $1.2 bill...most 5% over 2008 as patients chose to delay or fo... The market will, however, begin recovery in 2010,...ion growth rates of over 15%. MRG,s facial injecta...
Breaking Medicine Technology:Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2Simmons Firm's Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer 2Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 1Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 2Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 4Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 5Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 6Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 7Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4
...MELBOURNE, Australia, Feb. 11 Phosphagenics,Limit...PGNY) and Nestle,Nutrition (Nestle) today announce... establish the efficacy of Phosphagenics, Phospha ...vancing at three sites in Adelaide,Australia., Ba...ants, the,double-blind phase 2 trial, which is ful...
...BOULDER, Colo., and MONTREAL, Feb. 11 ,Pharmion (N...y announced that,the European Medicines Agency (EM...CD0103, a histone deacetylase (HDAC) inhibitor, as...acute myelogenous leukemia in the,European Union (...duct be,intended for the treatment of life-threate...
Other Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:11/30/2009)...y (EAU) and Europa Uomo, the European,advocacy mo... entered into an,affiliated partnership as part o...ve,patient awareness in Europe with regards to ur...sson, Secretary-General of the EAU: "Thanks to thi...will gain access to the latest information on,opt...
(Date:11/30/2009)...knows the enormous joy and comfort that an animal ...ts are considered important members of the family ...search now documents the value of the human-animal...llness, physical impairment, dementia, abuse and t...ated youth and adults. , In two articles in a re...
(Date:11/30/2009)...as launched a series of clinical trials in order t...t. This approach involves the application of perso...cells from the patient him or herself and designed...ve and frequent malignant tumours. The new therapy...d with the standard, first-line treatment involvin...
(Date:11/30/2009)...uot;My Two-Year Old Eats Octopus," gives meal...rything. , (PRWEB) Novemb...ouse? Do you find yourself acting as a short-orde... – one focusing on packing lunches, a second...l-life parents’ questions – introduce ...
(Date:11/30/2009)... so do knees, internal injuries, study finds, , ...you,re a middle-age weekend warrior who likes to h... A new study suggests that high levels of physical...hat could lead to osteoarthritis. , The study f...le who showed no symptoms and had a healthy weight...
Breaking Medicine News(10 mins):Health News:The therapeutic benefits of the human-animal bond 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:New Videos Help Parents of Picky Eaters 2Health News:New Videos Help Parents of Picky Eaters 3Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 3
...n,s reports of persistent, recent-onset symptoms l... difficulty eating or feeling full quickly and abd...d test may improve the early detection of ovarian ...h has found that when used alone, a simple four-qu...
... Garbose Family Special Delivery Unit at The Child...ind service for mothers,carrying fetuses with pren...e 22 Hundreds of families,gathered today to celeb...followed by the Center for Fetal Diagnosis and,Tre...
...truggling with the health fallout caused by a lack...y News) -- Most women don,t need a survey to tell ...eep-deprived and feel too sluggish to make it thro... women acknowledge that they just don,t get enough...
...n those under 80, could ease expected worldwide sh...ealthDay News) -- A blood substitute product calle... Phase III multi-center clinical trial, a new stud...) or an equivalent one unit (65 grams) of HBOC-201...
..., June 20 The United States,has provided $50,000 ...,organization Save the Children to assist people a...istrict of India., Shortages have emerged in rece...he United States, Save the,Children will assist po...
... June 20 The Department of,Agriculture is recomme...rom,Stump Acres Dairy farm in New Salem, York Coun...eria Monocytogenes contamination, Agriculture,Secr...quires they obtain,permits and be inspected to red...
Other Medicine News:Health News:Symptom screening plus a simple blood test improves early detection of ovarian cancer 2Health News:12th Annual Fetal Surgery Family Reunion Gathers Families From Across the U.S. and Canada 2Health News:12th Annual Fetal Surgery Family Reunion Gathers Families From Across the U.S. and Canada 3Health News:So Much to Do, So Little Sleep 2Health News:So Much to Do, So Little Sleep 3Health News:Blood Substitute Found Safe in Large Phase III Trial 2Health News:PA Agriculture Department Warns Consumers About Raw Milk Sold by York County Dairy 2
VascoScrew E 8/60 M
VascoScrew P 6/60 M
VascoScrew E 6/60 S
VascoScrew E 5/60 PU M
Medicine Products: